REG - Venture Life Group - Results of AGM

Venture LifeAnnouncement

22/05/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV2378Aa&default-theme=true

RNS Number : 2378A  Venture Life Group PLC  22 May 2023

22 May 2023

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Company")

 

Results of AGM

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the international self-care market, held its
Annual General Meeting ("AGM") earlier today at the offices of Simmons &
Simmons LLP, CityPoint, 1 Ropemaker St, London EC2Y 9SS.

Ordinary resolutions 1 to 6 were duly passed along with special resolution 8.
Special resolution 7 was not passed.

Proxy votes were received in respect of approximately 61% of the Company's
issued share capital and the final votes received in respect of each
resolution were as follows:

 Resolution                                                                    Number of votes for  % Votes for  Number of votes against  %       Number of votes withheld
 1.     To receive and adopt the reports of the Directors and auditor and      77,261,778           99.98%       13,683                   0.02%   963
 the audited accounts of the Company for the year ended 31 December 2022

 2.     To re-elect as a Director, Gianluca Braguti who seeks re-election      77,227,821           99.94%       46,239                   0.06%   2,364
 3.     To re-elect as a Director Jerry Randall who seeks re-election          77,203,609           99.94%       48,239                   0.06%   24,576
 4.     To appoint Mark Adams as Non-Executive Director                        77,252,547           99.97%       21,513                   0.03%   2,364
 5.     To appoint Evelyn Partners Limited as the auditor of the Company       77,248,712           99.97%       25,749                   0.03%   1,963
 until conclusion of the next AGM
 6.     THAT the Directors are authorised to allot shares in the Company       57,570,442           74.50%       19,703,618               25.50%  2,364
 7.     THAT, if Resolution 6 is passed, the Directors are authorised to       49,242,983           63.73%       28,031,077               36.27%  2,364
 allot equity securities for cash
 8.     The Company is authorised to make one or more market purchases of      68,942,257           89.22%       8,331,803                10.78%  2,364
 ordinary shares

 

 

 

For further information, please contact:

Venture Life Group PLC
 
   +44 (0) 1344 578004Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker)
                         +44 (0) 20 7397 8900

Stephen Keys / Camilla Hume (Corporate Finance)

Michael Johnson (Sales)

 

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong  (Corporate Finance)
 
+44 (0) 20 74963000

Jonathan Dighe (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal
infections and proctology, and dermo-cosmetics for addressing the signs of
ageing. Its products are sold in over 90 countries worldwide. The products,
which are typically recommended by pharmacists or healthcare practitioners,
are available primarily through pharmacies and grocery multiples. In the UK
and The Netherlands these are supplied direct by the company to retailers,
elsewhere they are supplied by the Group's international distribution
partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGNKBBPNBKDCPB